MLLCF (Molecular Partners AG) Momentum Rank: 10 (As of Jul. 31, 2026) — 150% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLCF Molecular Partners AG MLLCF
34 GF Score
Price $3.80
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG Momentum Rank?

Molecular Partners AG MLLCF 34 Momentum Rank is 10 as of Jul. 31, 2026, which is 150% above its 10-year median of 4.00. GuruFocus rates MLLCF with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

Molecular Partners AG has the Momentum Rank of 10.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Molecular Partners AG Momentum Rank Related Terms

MLLCF vs VRTX, REGN, RVMD: Momentum Rank Comparison

For the Biotechnology subindustry, Molecular Partners AG's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Molecular Partners AG Momentum Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Momentum Rank falls into.


MLLCF
34GF Score
Molecular Partners AG MLLCF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 10 mean?
Molecular Partners AG (MLLCF) has a Momentum Rank of 10 as of Jul. 31, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Molecular Partners AG and its competitors. This is 150% above median its historical median of 4.00. Over the past decade, Molecular Partners AG's Momentum Rank has ranged from 1.00 to 10.00.
Is Molecular Partners AG's Momentum Rank too high?
Molecular Partners AG's current Momentum Rank of 10 is 150% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Molecular Partners AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Momentum Rank compare to VRTX and REGN?
Molecular Partners AG's Momentum Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Molecular Partners AG's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Biotechnology company?
A good Momentum Rank depends on the Biotechnology industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Molecular Partners AG and its competitors. Molecular Partners AG's current Momentum Rank is 10, which is 150% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Molecular Partners AG (MLLCF) has a current Momentum Rank of 10. The current Momentum Rank is 10, which is 150% above median its 10-year median of 4.00. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Momentum Rank is 10 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score

Get the complete analysis for MLLCF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price